Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 03, 2022

SELL
$1.55 - $3.01 $1 - $3
-1 Reduced -0.0%
53,700 $86,000
Q2 2022

Aug 12, 2022

SELL
$1.39 - $3.12 $9,704 - $21,783
-6,982 Reduced 11.51%
53,701 $106,000
Q1 2022

May 16, 2022

SELL
$2.6 - $4.17 $114,223 - $183,196
-43,932 Reduced 41.99%
60,683 $184,000
Q4 2021

Feb 14, 2022

BUY
$3.64 - $7.78 $195,038 - $416,867
53,582 Added 104.99%
104,615 $380,000
Q3 2021

Nov 09, 2021

BUY
$6.01 - $8.71 $70,893 - $102,743
11,796 Added 30.06%
51,033 $402,000
Q2 2021

Aug 13, 2021

BUY
$6.02 - $9.64 $50,995 - $81,660
8,471 Added 27.53%
39,237 $285,000
Q1 2021

May 13, 2021

BUY
$9.17 - $14.8 $146,389 - $236,267
15,964 Added 107.85%
30,766 $290,000
Q4 2020

Feb 11, 2021

SELL
$8.92 - $13.29 $33,904 - $50,515
-3,801 Reduced 20.43%
14,802 $167,000
Q3 2020

Nov 12, 2020

SELL
$9.94 - $16.59 $27,225 - $45,440
-2,739 Reduced 12.83%
18,603 $199,000
Q2 2020

Aug 12, 2020

BUY
$12.07 - $19.34 $153,349 - $245,714
12,705 Added 147.1%
21,342 $324,000
Q1 2020

May 13, 2020

SELL
$12.5 - $22.04 $224,200 - $395,309
-17,936 Reduced 67.5%
8,637 $134,000
Q4 2019

Feb 10, 2020

BUY
$11.42 - $22.19 $130,439 - $253,454
11,422 Added 75.39%
26,573 $550,000
Q3 2019

Nov 14, 2019

SELL
$14.74 - $22.28 $7,723 - $11,674
-524 Reduced 3.34%
15,151 $274,000
Q2 2019

Aug 14, 2019

BUY
$18.35 - $30.34 $153,662 - $254,067
8,374 Added 114.7%
15,675 $307,000
Q1 2019

May 15, 2019

BUY
$19.76 - $29.57 $15,709 - $23,508
795 Added 12.22%
7,301 $202,000
Q4 2018

Feb 14, 2019

BUY
$18.39 - $26.3 $47,666 - $68,169
2,592 Added 66.22%
6,506 $145,000
Q3 2018

Nov 14, 2018

BUY
$15.54 - $22.86 $30,163 - $44,371
1,941 Added 98.38%
3,914 $89,000
Q2 2018

Aug 14, 2018

BUY
$16.49 - $21.55 $32,534 - $42,518
1,973 New
1,973 $41,000

Others Institutions Holding FIXX

About Homology Medicines, Inc.


  • Ticker FIXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 57,402,000
  • Description
  • Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...
More about FIXX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.